Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Other Non-Current Liabilities (2018 - 2025)

10x Genomics (TXG) has disclosed Other Non-Current Liabilities for 8 consecutive years, with $6.5 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 28.67% to $6.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.5 million through Dec 2025, up 28.67% year-over-year, with the annual reading at $6.5 million for FY2025, 28.67% up from the prior year.
  • Other Non-Current Liabilities hit $6.5 million in Q4 2025 for 10x Genomics, up from $6.4 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $10.1 million in Q3 2023 to a low of $3.0 million in Q4 2022.
  • Historically, Other Non-Current Liabilities has averaged $6.6 million across 5 years, with a median of $6.4 million in 2025.
  • Biggest five-year swings in Other Non-Current Liabilities: skyrocketed 473.85% in 2021 and later plummeted 63.88% in 2022.
  • Year by year, Other Non-Current Liabilities stood at $8.2 million in 2021, then plummeted by 63.88% to $3.0 million in 2022, then skyrocketed by 43.65% to $4.3 million in 2023, then increased by 17.64% to $5.0 million in 2024, then grew by 28.67% to $6.5 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for TXG at $6.5 million in Q4 2025, $6.4 million in Q3 2025, and $6.1 million in Q2 2025.